Tegafur
Information
- Drug Name
- Tegafur
- Description
- Entry(CIViC)
- 3
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| cancer |
DPYD c.1905+1G>A ( ENST00000370192.8 ) DPYD c.1905+1G>A ( ENST00000370192.8 ) |
A |
Predictive
|
Supports
|
Adverse Response | Common Germline | 5 | 23988873 | Detail |
| cancer |
DPYD p.Ile560Ser (p.I560S) ( ENST00000370192.8 ) DPYD p.Ile560Ser (p.I560S) ( ENST00000370192.8 ) |
A |
Predictive
|
Supports
|
Adverse Response | Common Germline | 5 | 23988873 | Detail |
| cancer | DPYD RS67376798 HOMOZYGOSITY DPYD RS67376798 HOMOZYGOSITY | A |
Predictive
|
Supports
|
Adverse Response | Common Germline | 5 | 23988873 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| The Clinical Pharmacogenomics Implementation Conso... | DPYD |
DPYD c.1905+1G>A ( ENST00000370192.8 ) DPYD c.1905+1G>A ( ENST00000370192.8 ) |
Adverse Response | true | CIViC Evidence | detail |
| The Clinical Pharmacogenomics Implementation Conso... | DPYD |
DPYD p.Ile560Ser (p.I560S) ( ENST00000370192.8 ) DPYD p.Ile560Ser (p.I560S) ( ENST00000370192.8 ) |
Adverse Response | true | CIViC Evidence | detail |
| The Clinical Pharmacogenomics Implementation Conso... | DPYD | DPYD RS67376798 HOMOZYGOSITY DPYD RS67376798 HOMOZYGOSITY | Adverse Response | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03406299 | Active, not recruiting | Phase 2 | Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer | April 19, 2018 | December 31, 2023 |
| NCT00378716 | Completed | Phase 3 | Combination Chemotherapy in Treating Patients With Resected Colon Cancer | February 1997 | April 2009 |
| NCT06396585 | Not yet recruiting | Phase 2 | The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction | August 1, 2024 | August 31, 2026 |
| NCT05914610 | Not yet recruiting | Phase 3 | Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer | September 1, 2023 | July 30, 2028 |
| NCT06383078 | Not yet recruiting | Phase 2 | HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer | April 20, 2024 | December 30, 2027 |
| NCT04135781 | Recruiting | Phase 3 | Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer | March 1, 2020 | October 31, 2024 |
| NCT06339619 | Recruiting | Phase 2 | Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma | March 11, 2024 | September 1, 2026 |
| NCT06354140 | Recruiting | Phase 2 | PPIO-008S-1 Combined With Tislelizumab in Patients With Primary Residual Node-negative Esophageal Squamous Cell Carcinoma (ESCC) After Radical Resection With Neoadjuvant Immunotherapy Combined With Chemotherapy, PHASE II STUDY | April 7, 2024 | April 30, 2028 |
| NCT05223088 | Recruiting | Phase 2 | Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer | October 31, 2021 | April 30, 2024 |
| NCT05817201 | Recruiting | Phase 2/Phase 3 | Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy | July 1, 2022 | December 31, 2024 |
| NCT03175705 | Unknown status | Phase 1 | Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC | May 1, 2017 | March 30, 2019 |
| NCT04216758 | Unknown status | Phase 2 | Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer | January 1, 2020 | December 31, 2020 |
| NCT03175679 | Unknown status | Phase 1 | Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC | May 1, 2017 | March 30, 2019 |
| NCT03204032 | Unknown status | Phase 2 | A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor | October 2016 | September 2018 |
| NCT03702491 | Unknown status | Phase 2 | Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma | August 10, 2018 | August 10, 2020 |